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Introduction
Dimethyl fumarate (DMF, Tecfidera) is an FDA-approved oral multiple sclerosis (MS) therapy that is one of a growing number of oral disease modifying therapies now available for the treatment of relapsing forms of MS. 1 DMF is proposed to function through a transcription factor, nuclear factor erythroid 2-like 2 (Nrf2), that can regulate antioxidant genes, thereby preventing neurodegeneration by inhibiting reactive oxygen and nitrogen species.
1 DMF is also used clinically in the treatment of psoriasis, where it alters cell adhesion molecules. 2 Although DMF is efficacious in MS and psoriasis, DMF-associated progressive multifocal leukoencephalopathy (PML) cases were reported in psoriasis patients and in an MS patient. 3, 4 PML was also reported in MS patients receiving natalizumab (Tysabri), a monoclonal antibody against integrin a4 (ITGA4/CD49d). Natalizumab blocks very late antigen-4 (VLA-4, a4b1 heterodimer), which is expressed on leukocytes including lymphocytes and monocytes, and prevents lymphocyte entry into the central nervous sytem (CNS). 5, 6 In view of natalizumab's action and the reported alteration of adhesion molecules by DMF, we tested the hypothesis that DMF might affect ITGA4 expression on circulating lymphocytes during murine experimental autoimmune encephalomyelitis (EAE) and in human Jurkat T cells. 
Material and Methods

EAE induction and treatment
Jurkat T cells
Jurkat T cells were maintained in (Roswell Park Memorial Institute) RPMI-1640 supplemented with 10% (fetal bovine serum) FBS, 50 lmol/L 2-mercaptoethanol and penicillin/streptomycin. Jurkat T cells (2.5 9 10 5 cells) were added to 96-well round bottom plates with varied concentrations of DMF and tert-Butylhydroquinone (tBHQ), an activator of Nrf2, in the presence or absence of anti-CD3 and anti-CD28 antibodies (1 lg/mL; BioLegend, San Diego, CA, USA). The cells were immunostained with FITC-anti-CD49d antibody (BioLegend) 42 h after stimulation, and analyzed using a BD LSR-II flow cytometer. DMF (50 and 100 mg/kg per s.i.d.) was orally administered into EAE mice from days 0 to 28 after immunization. The clinical scores were assessed daily. Data represent mean AE SEM (n = 8, P < 0.05; by two-way ANOVA). *P < 0.05 for 100 mg/kg treatment as compared to control by Bonferroni's multiple comparisons test. (D) Treatment effects. EAE mice were treated with DMF (n = 11) or fingolimod (n = 9) for 14 days (days [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] 
Results
DMF shows prevention but not therapeutic activity in EAE
Preventative effects of DMF on EAE were assessed by b.i.d. dosing as compared to a positive control (fingolimod). DMF and fingolimod significantly affected the development and severity of EAE as shown by lower clinical scores, decreased incidence, and delayed onset ( Fig. 1A and B). We also tested the preventative effects of daily (s.i.d.) DMF dosing on EAE (Fig. 1C) , however, this paradigm showed inefficient (albeit significant) prevention of EAE (Fig. 1B and C) .
To investigate therapeutic effects of DMF, DMF was delivered b.i.d near peak clinical scores. DMF treatment had no effect on therapeutic clinical scores even after 14 days of b.i.d. treatment (Fig. 1D) . As expected, fingolimod (positive control) produced a reduction in clinical scores as compared to control groups.
DMF inhibits ITGA4 expression on EAE lymphocytes, without changing total WBC counts CBC tests were carried out to examine if DMF shared fingolimod's known lymphopenic effects on EAE ( Fig. 2A) . DMF treatment did not significantly affect blood cell subset levels, although it trended towards mild lymphocytosis. In contrast, fingolimod treatment reduced the level of peripheral WBCs, lymphocytes, and neutrophils (no change in monocyte levels) as anticipated. 8 Furthermore, the relative proportion of CD3 + T cells and B220 + B cells in DMF-treated EAE mice showed no difference versus controls, whereas the relative proportion of these cell types was reduced in fingolimod-treated EAE mice (Fig. 2B) .
Alteration of adhesion molecules by DMF and a possible natalizumab-like activity including mild lymphocytosis, 5 led us to examine ITGA4 expression on circulating lymphocytes by flow cytometry (Fig. 2C and  D) . Without affecting the number of lymphocytes, DMF treatment significantly inhibited ITGA4 expression on both CD3 + T cells (30% reduction, Fig. 2C ) and B220 + B cells (40% reduction, Fig. 2D ), most notably in the ITGA4 high population. These results indicate that DMF downregulates ITGA4 expression on lymphocytes.
DMF inhibits ITGA4 expression on activated human Jurkat T cells in a manner distinct from Nrf2 activation
Toward validating murine results with EAE as potentially relevant to MS, ITGA4 expression was assessed on human Jurkat T cells in culture (Fig. 3A and B) . Under basal (un-activated) conditions, DMF exposure did not produce significant changes in ITGA4 expression. In contrast, under activated conditions (antibody-mediated crosslinking of CD3 and CD28), DMF inhibited ITGA4 expression in a concentration-dependent manner. These data support selective effects of DMF on activated lymphocytes to reduce cell surface ITGA4 expression.
To assess relationships between Nrf2 activation and DMF-dependent changes in ITGA4 expression, both unactivated and activated Jurkat T cells were cultured with an activator of Nrf2, tBHQ. 9 In stark contrast to DMF, tBHQ increased ITGA4 expression in both activated and un-activated Jurkat T cells in a concentration-dependent manner ( Fig. 3C and D) . These results support human relevance of DMF in reducing ITGA4 expression, which appears to be distinct from and counter-regulatory to Nrf2 activation.
Discussion
In this study, we show that DMF inhibited ITGA4 expression on CD3 + T and B220 + B cells in EAE mice, implicating downregulation of a4b1 integrin (VLA-4) as well as a distinct integrin heterodimer, a4b7 integrin. Consistent with these results, natalizumab-treated mice and both CD4 + T-cell-specific and CD19 + B-cell-specific ITGA4 knockout mice exhibit milder EAE disease. [10] [11] [12] Supporting relevance to efficacy in MS is the consistent effect of DMF in reducing ITGA4 expression on activated human Jurkat T cells in a manner distinct from Nrf2 activation. Other possible mechanisms of action that are not ruled out and were not assessed by this study include DMF acting through hydroxycarboxylic acid receptor 2. 13 Our data that ITGA4 high populations were selectively affected by DMF treatment may have clinical implications. The DEFINE 14 and CONFIRM studies 15 on relapsing MS observed that DMF was more effective in younger patients than older patients. VLA-4 levels on CD3 + T cells are significantly higher in younger adults (~20%), 16 therefore younger patients may be more responsive to DMF exposure that selectively affects ITGA4 high populations. It is also notable that, in the PRISMS trial, 17 interferon b-1a (IFNb1a) treatment also reduced VLA-4 expression by about 25% and the responders to IFNb1a also showed higher baseline levels of VLA-4 than nonresponders. These results support the reduction in VLA-4 expression on lymphocytes as a shared mechanism amongst several MS-modifying drugs including DMF. The observed differences in DMF efficacy between preventative and therapeutic paradigms are also consistent with this shared mechanism as an established anti-VLA-4 antibody treatment is similarly ineffective in a therapeutic paradigm and moreover, exacerbates EAE. 18 VLA-4 inhibition is associated with a serious adverse event, PML, as has been well documented in natalizumab use. 5 From this perspective, VLA-4 inhibition by DMF could help to explain recent PML cases. 3, 4 Considering results of the PRISMS trial, 17 a recent case of PML in an MS patient (with a common variable immunodeficiency syndrome) after IFNb1a monotherapy supports the role of VLA-4 in PML independent of natalizumab or DMF treatment. 19 However, the much lower incidence of PML in both the interferon and DMF cases, as compared to natalizumab, underscores the existence of additional variables contributing to PML. The blockade of VLA-4 on lymphocytes by natalizumab dampens immuno-surveillance that may cause PML, 6 whereas selective actions of DMF on ITGA4 high lymphocytes could reduce the number of circulating encephalitogenic cells, 20 which is also consistent with the preventative but not therapeutic effects of DMF in EAE. Thus, this putative mechanism offers a possible explanation for both DMF efficacy and rare cases of PML, underscoring a need for balance between efficacy and adverse events mediated by the same molecular target.
